{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T14:35:16Z","timestamp":1772462116678,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"DGRh","award":["2316-0-0, 2016-2-02"],"award-info":[{"award-number":["2316-0-0, 2016-2-02"]}]},{"name":"IZKF","award":["2383-0-0"],"award-info":[{"award-number":["2383-0-0"]}]},{"name":"Max Eder Research Fellowship Program of the German Cancer Aid"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Systemic sclerosis (SSc) is a potentially fatal autoimmune disease that leads to extensive fibrosis of the skin and internal organs. Invariant natural killer T (iNKT) cells are potent immunoregulatory T lymphocytes being able to orchestrate dysregulated immune responses. The purpose of this study was to evaluate numbers and function of iNKT cells in patients with SSc and to analyze their correlation with disease parameters.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Human iNKT cells from 88 patients with SSc and 33 healthy controls were analyzed by flow cytometry. Their proliferative capacity and cytokine production were investigated following activation with CD1d ligand \u03b1-galactosylceramide (\u03b1-GalCer).<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We observed an absolute and relative decrease of iNKT cells in patients with SSc compared with healthy controls. Interestingly, the subtype of SSc, disease severity, or treatment with immunosuppressive drugs did not affect iNKT cell numbers. However, T helper (Th) cell immune polarization was biased towards a Th17 immunophenotype in SSc patients. Moreover, iNKT cells from patients with SSc showed a significantly decreased expansion capacity upon stimulation with \u03b1-GalCer.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>iNKT cells are deficient and functionally impaired in patients with SSc. Therefore, adoptive transfer strategies using culture-expanded iNKT cells could be a novel approach to treat SSc patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-019-1991-y","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T11:20:13Z","timestamp":1571138413000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Invariant natural killer T cells are functionally impaired in patients with systemic sclerosis"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0201-0686","authenticated-orcid":false,"given":"Ann-Christin","family":"Pecher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Kettemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Asteriti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannes","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silke","family":"Duerr-Stoerzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hildegard","family":"Keppeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joerg Christoph","family":"Henes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhild","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens","family":"Hinterleitner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy-Ann","family":"Secker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corina","family":"Schneidawind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lothar","family":"Kanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Schneidawind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,15]]},"reference":[{"key":"1991_CR1","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3899\/jrheum.111106","volume":"39","author":"DE Furst","year":"2012","unstructured":"Furst DE, Fernandes AW, Lorga SR, Greth W, Bancroft T. Epidemiology of systemic sclerosis in a large managed care population. J Rheumatol. 2012;39:784\u20136.","journal-title":"J Rheumatol"},{"key":"1991_CR2","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1093\/rheumatology\/keu285","volume":"54","author":"V Nagaraja","year":"2015","unstructured":"Nagaraja V, Denton CP, Khanna D. Old medications and new targeted therapies in systemic sclerosis. Rheumatology. 2015;54:1944\u201353.","journal-title":"Rheumatology."},{"key":"1991_CR3","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","volume":"76","author":"M Elhai","year":"2017","unstructured":"Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017;76:1897\u2013905.","journal-title":"Ann Rheum Dis"},{"key":"1991_CR4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/j.1399-0039.2009.01256.x","volume":"73","author":"L Wu","year":"2009","unstructured":"Wu L, Gabriel CL, Parekh V, Van Kaer L. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities. Tissue Antigens. 2009;73:535\u201345.","journal-title":"Tissue Antigens"},{"key":"1991_CR5","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.tips.2005.03.005","volume":"26","author":"CR Berkers","year":"2005","unstructured":"Berkers CR, Ovaa H. Immunotherapeutic potential for ceramide-based activators of iNKT cells. Trends Pharmacol Sci. 2005;26:252\u20137.","journal-title":"Trends Pharmacol Sci"},{"key":"1991_CR6","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1146\/annurev.immunol.25.022106.141711","volume":"25","author":"A Bendelac","year":"2007","unstructured":"Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol. 2007;25:297\u2013336.","journal-title":"Annu Rev Immunol"},{"key":"1991_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/156652409787314534","volume":"9","author":"L Wu","year":"2009","unstructured":"Wu L, Van KL. Natural killer T cells and autoimmune disease. Curr Mol Med. 2009;9:4\u201314.","journal-title":"Curr Mol Med"},{"key":"1991_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1365-2249.2012.04625.x","volume":"171","author":"Y Simoni","year":"2013","unstructured":"Simoni Y, Diana J, Ghazarian L, Beaudoin L, Lehuen A. Therapeutic manipulation of natural killer (NK) T cells in autoimmunity: are we close to reality? Clin Exp Immunol. 2013;171:8\u201319.","journal-title":"Clin Exp Immunol"},{"key":"1991_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3109\/08916931003782130","volume":"44","author":"S Caielli","year":"2011","unstructured":"Caielli S, Sorini C, Falcone M. The dangerous liaison between iNKT cells and dendritic cells: does it prevent or promote autoimmune diseases? Autoimmunity. 2011;44:11\u201322.","journal-title":"Autoimmunity."},{"key":"1991_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2567.2007.02647.x","volume":"122","author":"CJ Montoya","year":"2007","unstructured":"Montoya CJ, Pollard D, Martinson J, Kumari K, Wasserfall C, Mulder CB, et al. Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11. Immunology. 2007;122:1\u201314.","journal-title":"Immunology."},{"key":"1991_CR11","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1182\/blood-2014-05-576017","volume":"124","author":"D Schneidawind","year":"2014","unstructured":"Schneidawind D, Pierini A, Alvarez M, Pan Y, Baker J, Buechele C, et al. CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells. Blood. 2014 20;124:3320\u20138.","journal-title":"Blood."},{"key":"1991_CR12","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1084\/jem.182.4.1163","volume":"182","author":"T Sumida","year":"1995","unstructured":"Sumida T, Sakamoto A, Murata H, Makino Y, Takahashi H, Yoshida S, Nishioka K, Iwamoto I, Taniguchi M. Selective reduction of T cells bearing invariant V alpha 24J alpha Q antigen receptor in patients with systemic sclerosis. J Exp Med. 1995;182:1163\u20138.","journal-title":"J Exp Med"},{"key":"1991_CR13","first-page":"283","volume":"32","author":"V Riccieri","year":"2005","unstructured":"Riccieri V, Parisi G, Spadaro A, et al. Reduced circulating natural killer T cells and gamma\/delta T cells in patients with systemic sclerosis. J Rheumatol. 2005;32:283\u20136.","journal-title":"J Rheumatol"},{"key":"1991_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nri1531","volume":"5","author":"L Van Kaer","year":"2005","unstructured":"Van Kaer L. alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat Rev Immunol. 2005;5:31\u201342.","journal-title":"Nat Rev Immunol"},{"key":"1991_CR15","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1056\/NEJMra0707449","volume":"361","author":"P Miossec","year":"2009","unstructured":"Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361:888\u201398.","journal-title":"N Engl J Med"},{"key":"1991_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.imlet.2017.09.007","volume":"195","author":"C Chizzolini","year":"2018","unstructured":"Chizzolini C, Dufour AM, Brembilla NC. Is there a role for IL-17 in the pathogenesis of systemic sclerosis? Immunol Lett. 2018;195:61\u20137.","journal-title":"Immunol Lett"},{"key":"1991_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/08916934.2017.1416467","volume":"51","author":"RSG Gon\u00e7alves","year":"2018","unstructured":"Gon\u00e7alves RSG, Pereira MC, Dantas AT, Almeida AR, Marques CDL, Rego MJBM, et al. IL-17 and related cytokines involved in systemic sclerosis: perspectives. Autoimmunity. 2018;51:1\u20139.","journal-title":"Autoimmunity."}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1991-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-019-1991-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1991-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T23:23:27Z","timestamp":1602631407000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-019-1991-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,15]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1991"],"URL":"https:\/\/doi.org\/10.1186\/s13075-019-1991-y","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,15]]},"assertion":[{"value":"30 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the institutional review board of the Eberhard-Karls-University Tuebingen (IRB approval number 114\/2016BO) to be in accordance with the ethical standards and with the Helsinki Declaration of 1975, as revised in 2013.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"212"}}